Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Neuropharmacology. 2015 Jun 10;97:464–475. doi: 10.1016/j.neuropharm.2015.05.038

Figure 4.

Figure 4

Effects of small molecule PSD95-nNOS inhibitors on formalin-induced pain behaviors. A, B IC87201 (4 and 10 mg/kg i.p.) suppresses formalin-induced nociceptive behaviors during phase 2A (n = 6–8). C, D ZL006 (4 and 10 mg/kg i.p.) suppresses formalin-induced nociceptive behaviors during phase 1 and phase 2A but not during phase 2B (n = 6–8). E, F Comparison of maximally efficacious doses of small molecule inhibitors with NMDAR antagonist MK-801 (0.1 mg/kg i.p.) (n = 6–8). *p < 0.05; **p < 0.01; ***p < 0.001 versus control.